ARPA-H Launches $139M EVIDENT Initiative to Advance Behavioral Health Therapies

Overview

The Advanced Research Projects Agency for Health (ARPA-H) has announced initial research teams for the $139.4 million EVIDENT initiative, aimed at developing objective, FDA-ready clinical endpoints to validate rapid-acting behavioral health treatments. This initiative supports innovative therapies including neuromodulation, digital interventions, and psychedelics, with at least $50 million matched to state investments in psychedelic research for serious mental illness.

Background

Behavioral health disorders affect half of all Americans during their lifetime, with veterans experiencing even higher rates. Despite a dramatic increase in spending on behavioral health and substance use treatments—from $40.9 billion in 2000 to over $140 billion annually—progress has been limited by a lack of objective tools to measure treatment efficacy. The EVIDENT initiative seeks to transform mental health care by generating scalable, objective measures that enable personalized, data-driven treatment approaches and accelerate regulatory approval of effective therapies.

Data Highlights

Key Findings

• EVIDENT will invest up to $139.4 million to develop objective, FDA-ready endpoints for rapid-acting behavioral health therapies.
• At least $50 million will match state investments in psychedelic research targeting serious mental illness.
• The initiative addresses four core questions: objective measurement, treatment dynamics, treatment response prediction, and shared data infrastructure.
• Research teams span multi-omics, neuromodulation, psychedelics, microbiome interventions, wearable data integration, and clinical trials across multiple institutions.
• EVIDENT aims to shift behavioral health care from subjective, trial-and-error approaches to precise, personalized, data-driven treatment strategies.
• The initiative supports accelerated regulatory approval and reduced development costs for therapies addressing depression, anxiety, addiction, and PTSD.

Clinical Implications

Clinicians may soon have access to objective biomarkers and predictive tools that enable earlier and more accurate assessment of behavioral health treatment efficacy. This could reduce the reliance on subjective scales and trial-and-error prescribing, leading to faster relief and personalized care for patients with mental health disorders. Additionally, the integration of real-world data and novel therapies like psychedelics may expand effective treatment options.

Conclusion

The EVIDENT initiative represents a significant advancement in behavioral health research by fostering objective measurement and validation of rapid-acting therapies. Its success could transform mental health care delivery, making treatments more precise, effective, and accessible for millions of Americans.

References

1. ARPA-H/HHS 2024 -- ARPA-H Unveils Initial Research Teams for $139 Million EVIDENT Initiative